Earendil Labs alternatives and competitors

BioMap builds large AI models of protein biology and uses them to find drug targets and design biologic drugs, working with pharmaceutical partners.

LabGenius designs antibody drugs for cancer using a machine learning engine wired into its own robotic lab, and develops them through a mix of partnerships and a wholly owned pipeline.

Absci designs antibodies with generative AI and develops them as its own medicines and with partners.

A-Alpha Bio measures how proteins bind to each other at enormous scale and uses that data to train AI that designs antibodies.

Drug discovery company built around super resolution live cell fluorescence microscopy, applying advanced optics descended from Nobel recognized single molecule imaging work together with machine learning to track how individual proteins behave and move inside living cells, rather than…

Biolojic Design uses machine learning to design antibodies that do more than block a target: epitope specific agonists and antagonists, conditional binders, and what it calls multibodies, single symmetrical antibodies that bind more than one target on the same arm.

Galux designs protein therapeutics with an AI platform that it pairs with the physics of how proteins fold. It is based in Seoul and works through pharmaceutical partnerships.

XtalPi is a drug and materials discovery company founded in Boston in 2015 by three MIT postdoctoral physicists, headquartered in Shenzhen and listed on the Hong Kong Stock Exchange (2228) since 2024.

Superluminal Medicines chases the same target class as Nabla Bio and Antiverse and attacks it from the opposite direction.

Generate:Biomedicines, a Somerville, Massachusetts company founded by Flagship Pioneering in 2018 and listed on Nasdaq since February 2026, designs protein medicines with machine learning rather than finding them in nature.